- AU$2.51bn
- AU$2.52bn
- $17.20m
Brief: Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter
ASX-listed Mesoblast surges on US Medicare billing approval for key drug
Brief: Mesoblast Enters Option To Issue $50 Million Convertible Notes
ASX-listed Mesoblast's shares tank 10% on widening annual loss
Australian healthcare stocks fall most since 2020, dragged lower by CSL
ASX-listed Mesoblast jumps as US FDA paves way for heart failure drug
Australia's Mesoblast gains as US FDA grants 7-year orphan-drug status for Ryoncil
Brief: Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs
Brief: Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs
Brief: Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil
ASX-listed Mesoblast climbs on Ryoncil pricing information release
Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index
Brief: Mesoblast Added To S&P Asx200 Index
Brief: Mesoblast Says HY Loss Attributable $47.9 Million
Brief: Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares
Brief: Mesoblast Says Raises A$260 Million For Ryoncil Commercial Launch
Australia's Mesoblast slides on discounted placement
Brief: Mesoblast Ltd Seeks Trading Halt
Mesoblast gains on FDA nod for graft-versus-host disease cell therapy